Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy: Correspondence
2018
Impaired glucose metabolism (IGM) with hyperglycemia represents
one of the most frequently observed adverse events (AE) during
nilotinib therapy of chronic myeloid leukemia (CML). The exact
mechanism of IGM remains controversial. Although a case report
has shown a decrease in insulin secretion1 , our previous pilot
data suggested development of insulin resistance as a possible
mechanism.2 In this prospective study we aimed to confirm
results from our pilot study using a larger cohort of CML
patients treated with nilotinib and to compare results with
data obtained on control groups receiving imatinib and
dasatinib.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
5
References
7
Citations
NaN
KQI